Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
Abstract Background Treatment of Hepatitis C virus (HCV) infection has evolved from interferon (IFN)-based treatments to direct-acting antivirals (DAAs). Patients with HCV have an elevated psychiatric morbidity (including substance abuse) and patients with such comorbidity have often been excluded f...
Main Authors: | Isak Sundberg, Anders Lannergård, Mia Ramklint, Janet L. Cunningham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12888-018-1735-6 |
Similar Items
-
New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01) -
Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients
by: Curtis L. Cooper, et al.
Published: (2017-11-01) -
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01) -
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01) -
Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India
by: Varun Gupta, et al.
Published: (2017-01-01)